RESUMO
Objective:To observe the clinical efficacy of compound Huanggen granules combined with Entecavir tablets for patients with chronic hepatitis B with syndrome of collateral retardation due to blood stasis. Method:The 130 patients with chronic hepatitis B with syndrome of collateral retardation due to blood stasis were randomly divided into observation group and control group by using random number table method. The 65 patients in observation group were treated with compound Huanggen granules combined with Entecavir tablets， and 65 patients in control group were treated with Entecavir tablets orally. The changes of liver function ［alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， total bilirubin（TBIL）， albumin（Alb）］ ， coagulation function ［prothrombin time（PT）， activated partial thromboplastin time（APTT）， thrombin time（TT）， fibrinogen（FIB）］， serum Hepatitis B Virus DNA（HBV DNA） levels， hepatitis B e antigen quantification（HBeAg）， stiffness of the liver， liver imaging （portal vein width， spleen thickness）， liver histopathology knodell HAI classification for chronic hepatitis， and changes in ishak fibrosis score at 24，48 weeks were observed in both groups. Result:After 48 weeks， the indexes of the two groups were improved to different degrees （P<0.05，P<0.01）， serum HBV DNA negative conversion rate， liver function， coagulation index， liver stiffness， portal vein diameter， Knodell HAI grade portal inflammation， interface activity， hepatic lobular activity， and Ishak fibrosis score in observation group were better than those in the control group （P<0.05）. Patients in the control group had no significant improvement in liver lobular activity after treatment in the Knodell HAI classification of chronic hepatitis. Conclusion:Compound Huanggen granules combined with Entecavir tablets are more effective in treating patients with chronic hepatitis B with syndrome of collateral retardation due to blood stasis than Entecavir tablets alone. The combination of two drugs helps to improve the rapid response rate of HBV DNA， and has a better effect on improving liver function， controlling the development of liver fibrosis and preventing related complications.